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Abstract 
Objectives:  
To test the feasibility of a randomised trial in muscle invasive bladder cancer (MIBC) 
and compare outcomes in patients who receive neoadjuvant chemotherapy followed by 
radical cystectomy or selective bladder preservation, where definitive treatment 
(cystectomy or radiotherapy) is determined by response to chemotherapy. 
Patients and methods 
SPARE is a multicentre randomised controlled trial comparing radical cystectomy and 
selective bladder preservation in patients with MIBC staged T2-3 N0 M0, fit for both 
treatment strategies and receiving three cycles of neoadjuvant chemotherapy.  
Patients were randomised between radical cystectomy and selective bladder 
preservation prior to a cystoscopy after cycle three of neoadjuvant chemotherapy. 
Patients with ≤T1 residual tumour received a fourth cycle of neoadjuvant chemotherapy 
in both groups, followed by radical radiotherapy in the selective bladder preservation 
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group and radical cystectomy in in the radical cystectomy group; non-responders in 
both groups proceeded immediately to radical cystectomy following cycle three.  
Feasibility study primary endpoints were accrual rate and compliance with assigned 
treatment strategy. The phase III trial was designed to demonstrate non-inferiority of 
selective bladder preservation in terms of overall survival in patients whose tumours 
responded to neoadjuvant chemotherapy. Secondary endpoints included patient 
reported quality of life, clinician assessed toxicity, loco-regional recurrence free survival 
and rate of salvage cystectomy after bladder preservation. 
Results 
Trial recruitment was challenging and below the predefined target with 45 patients 
recruited in 30 months (25 radical cystectomy; 20 selective bladder preservation). Non-
compliance with assigned treatment strategy was frequent, 6/25 patients (24%) 
randomised to radical cystectomy received radiotherapy.  
Long term bladder preservation rate was 11/15 (73%) in those who received 
radiotherapy per protocol. Overall survival was not significantly different between 
groups.  
Conclusions:  
Randomising MIBC patients between radical cystectomy and selective bladder 
preservation based on response to neoadjuvant chemotherapy was not feasible in the 
UK health system. Strong clinician and patient preferences for treatments impacted 
willingness to undergo randomisation and acceptance of treatment allocation. Due to 
the small number of participants, firm conclusions about disease and toxicity outcomes 
cannot be drawn.  
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Introduction 
Achieving local disease control is a critical step in treating muscle invasive bladder 
cancer (MIBC). A common approach is surgical removal of the bladder and adjacent 
organs - radical cystectomy. Despite being a successful approach to cancer control, this 
is a major operation, in an often unfit and/or elderly population. It requires formation 
of a urinary diversion and has substantial associated morbidity and mortality rates (1, 
2). 
 
Radical radiotherapy (RT) is an alternative to cystectomy (3, 4). It preserves a 
functioning bladder and avoids the risks of major surgery, but does not achieve local 
control for all patients and, if unsuccessful, requires subsequent salvage cystectomy, 
which can be challenging (5). The relative efficacy of radiotherapy and cystectomy has 
been debated extensively but, as randomised data are lacking, comparisons have been 
largely based on retrospective series where inherent biases can make interpretation 
difficult (4, 6, 7). UK bladder cancer treatment guidelines released in 2015 recommend 
that patients with muscle invasive bladder cancer are offered a choice of radical 
cystectomy or radiotherapy with a radiosensitiser (8). 
 
There also exists a paucity of comparative data on the effects of both treatment options 
on patients’ quality of life. Radical cystectomy has been found to have a substantial 
negative impact on health related quality of life in the first year postoperatively (9), 
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whilst patients who have received radiotherapy experience greater gastrointestinal 
dysfunction (10).  
 
Several groups have hypothesised that radiotherapy would be more attractive as a 
treatment option if it were possible to select patients with tumours most likely to 
respond. This would minimise the need for salvage cystectomy by undertaking 
immediate radical cystectomy for patients predicted to have less chance of cure with 
radiotherapy.  
 
Neoadjuvant chemotherapy before radical treatment improves survival in MIBC (11, 
12) and studies have suggested that tumours which respond to neoadjuvant 
chemotherapy may achieve higher rates of local control with radiotherapy than those 
which don’t (12, 13). Utilising chemotherapy in this way to select patients for 
radiotherapy achieved high levels of long term bladder preservation and avoided the 
need for surgery in most patients (14, 15). To test the efficacy of this approach we 
planned a randomised trial, with an initial feasibility study to compare, after 
neoadjuvant chemotherapy, a selective bladder preservation strategy with patients 
undergoing radical cystectomy.  
 
Patients and methods  
Study design 
SPARE (CRUK/07/011) was a multicentre phase III randomised controlled trial with an 
initial feasibility study (Figure 1). The aims of the feasibility study were to determine 
viability of accrual for the phase III trial and assess compliance with the assigned 
treatment strategy. There was an embedded qualitative research programme, which has 
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been previously reported (16, 17). The phase III trial was designed to determine if 
overall survival (OS) following bladder preservation is non-inferior to that following 
radical cystectomy for patients whose tumours respond to neoadjuvant chemotherapy.  
 
Patients were recruited at UK NHS Trusts. All Trusts providing trial treatment had to 
provide details of surgical activity including morbidity and mortality rates for central 
review and confirmation of completion of a radiotherapy quality assurance program 
prior to activation. Randomisation was by telephone to the Clinical Trials and Statistics 
Unit, Institute of Cancer Research (ICR-CTSU). Participants were assigned 1:1 between 
selective bladder preservation and radical cystectomy using computer generated 
random permuted blocks (size 6 and 8), stratified by centre. Treatment allocation was 
not masked. 
 
Patients 
Eligible patients provided written informed consent, were receiving neoadjuvant 
chemotherapy and fit for radiotherapy and surgery, at least 18 years old, had T2-T3 N0 
M0 transitional cell carcinoma of the bladder and WHO performance status 0-1, with 
satisfactory haematological profile and kidney function. Key exclusion criteria were 
widespread carcinoma in situ (CIS), simultaneous upper tract, urethral or prostatic 
urethral TCC, untreated hydronephrosis and invasive malignancy in the previous 5 
years.   
Initially treatment allocation took place during cycle two of neoadjuvant chemotherapy. 
Based on findings of the qualitative recruitment investigation (17), this timeframe was 
amended in August 2009 to allow randomisation at any time prior to a cystoscopy 
following cycle three (C3) of neoadjuvant chemotherapy.  
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Treatments:  
All participants received neoadjuvant chemotherapy. Gemcitabine (1000mg/m2 day 1 
and day 8) and cisplatin (70mg/m2) repeated every 21 days was recommended. All 
patients had a cystoscopy and tumour bed biopsy under general anaesthetic after cycle 
3 of neoadjuvant chemotherapy, with subsequent treatment dependent on response. 
 
Patients with pT2 or greater disease in both randomised groups proceeded immediately 
to radical cystectomy within 6 weeks of cycle 3. Patients with histological downstaging 
(pT1 or less), or a macroscopically normal bladder were classified as responders and 
received cycle 4 of neoadjuvant chemotherapy with subsequent treatment determined 
by randomised allocation. Patients receiving radiotherapy were permitted to receive 
concomitant radiosensitising chemotherapy. 
 
Selective bladder preservation group 
Patients whose tumours responded to neoadjuvant chemotherapy started radiotherapy 
to the bladder 4-6 weeks after cycle 4. Two fractionation schedules in standard use in 
the UK were permitted (55Gy/20 fractions or 64Gy/32 fractions). The planning target 
volume was the bladder plus 1.5cm margin, delivered by 3D conformal techniques.  
 
Radical cystectomy group 
Patients whose tumours responded to neoadjuvant chemotherapy received radical 
cystectomy 4-6 weeks after cycle 4. Radical cystectomy consisted of resection of the 
bladder, prostate and seminal vesicles in men and bladder, uterus, ovaries and upper 
vagina in women. Pelvic lymphadenectomy, removing a minimum of 10 lymph nodes, 
was mandated and recommended to include dissection of obturator nodes and external 
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iliac nodes to the level of the iliac bifurcation and internal iliac nodes from the right and 
left side of pelvis. The lateral limit of the dissection was the genito-femoral nerve on the 
psoas muscle and medial and posterior limits represented by the obturator nodes.  
Orthotopic reconstruction using small or large bowel was encouraged however 
standard ileal conduit formation was also permitted . 
 
Trial assessments 
Prior to neoadjuvant chemotherapy, patients underwent physical examination, 
haematological and biochemical assessment, CT scan of pelvis, chest X-ray or CT, and 
maximal cystoscopic resection of tumour. Tumour control was assessed by physical 
examination, chest x-ray and cystoscopy (if applicable) with follow up as shown in 
Figure 1. Adverse events were graded using Common Toxicity Criteria (CTC) version 3 
(18). Patient reported outcomes were collected, using paper EORTC general cancer and 
MIBC modules (QLQ-C30 and QLQ-BLM30). (19) 
 
Statistical considerations 
Endpoints 
The primary endpoints of the feasibility study were accrual rate, bladder preservation 
rate in the selective bladder preservation arm and cystectomy rate in the radical 
cystectomy arm. For the phase III component, the primary endpoint was 5 year survival. 
Secondary endpoints were treatment compliance, rate of salvage cystectomy, toxicity, 
patient-reported quality of life and loco-regional recurrence free (LRFS) and metastasis 
free (MFS) survival. For this analysis OS was treated as a secondary endpoint.  
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Sample size 
The phase III trial was powered to evaluate non-inferiority in the proportion of patients 
alive at five years between selective bladder preservation and radical cystectomy in 
those patients whose tumours responded to neoadjuvant chemotherapy. Seventy 
percent 5-year survival was assumed (14) with the aim of excluding a decrease of 8% or 
more in the selective bladder preservation group (corresponding to a critical hazard 
ratio (HR) for non-inferiority of 1.34). Assuming an 80% neoadjuvant chemotherapy 
response rate, 1015 patients would have been required to conclude non-inferiority 
(80% power, one-sided α=0.05). For the phase III study to be considered feasible it was 
recommended that 110 patients be randomised during the first two years, however this 
was amended to three years, or a sustainable accrual rate of at least 6 patients per 
month, in August 2009 with the endorsement of the independent Trial Steering 
Committee (17). An analysis of the feasibility stage was planned to assess compliance 
with the bladder preservation strategy with the aim of excluding an initial bladder 
preservation rate of less than 60%. This stop/go criterion was based on a single arm 
phase II design and required 39/55 patients in the SBP arm to undergo radiotherapy 
following response to neoadjuvant chemotherapy to warrant continuation to phase III.  
 
Statistical analysis 
All randomised participants are included. The number of neoadjuvant chemotherapy 
responses was compared between groups using Fisher’s exact test. Compliance with 
allocated treatment strategy was assessed by the proportion of patients: (i) with 
response after cycle 3 who received cycle 4 neoadjuvant chemotherapy and (ii) 
undergoing allocated treatment as their definitive treatment overall (i.e. cystectomy in 
the radical cystectomy arm, bladder preservation in selective bladder preservation arm 
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responders and cystectomy in selective bladder preservation arm non-responders). In 
the selective bladder preservation group, bladder preservation rate (BPR) was the 
proportion of patients who did not require cystectomy following radiotherapy both 
overall and in the subset who received RT according to protocol guidelines, ie in the 
population who responded to chemotherapy and received cycle 4. Unless otherwise 
stated, proportions are presented with exact binomial 95% confidence intervals (CI).  
 
Worst grade adverse events were compared by definitive treatment received and time 
to grade 3-4 event was estimated using Kaplan-Meier methods. 
 
Time to event endpoints were assessed using Kaplan-Meier methods in the population 
of responders in both groups, and repeated according to both intention to treat (ITT) 
and definitive treatment received. Treatment effects were estimated using unadjusted 
Cox regression models with a HR<1 indicating benefit for selective bladder preservation 
in the ITT analysis or radiotherapy for the treatment received analysis. OS was defined 
as time to death from any cause; time to loco-regional recurrence (LRR) was calculated 
to first non-muscle invasive (NMIBC) or muscle invasive (MIBC) recurrence in the 
bladder or recurrence in the pelvic nodes; MFS was time to the first of distant 
recurrence or death; disease specific survival (DSS) was time to death following nodal 
or metastatic recurrence or unsalvageable local recurrence. All times are calculated 
from randomisation.  
 
Quality of life data was analysed by treatment received and data were scored and 
missing data handled in accordance with the EORTC QLQ-C30 scoring manual (20). For 
each QLQ-C30 subscale, mean change from baseline was calculated, with 99% CI, for 
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each group at each time point and longitudinal plots of change from baseline were 
produced. Differences between groups in mean change from baseline to 12 months 
were assessed using ANCOVA, adjusting for baseline score. 
 
Analyses are based on a snapshot of the database taken on 30th September 2014 and 
performed using Stata (21). 
 
Research Governance 
SPARE was funded by Cancer Research UK (CRUK/07/011, C1491/A9895). The study is 
registered (ISRCTN61126465), sponsored by ICR and approved by the South East 
Multicentre Research Ethics Committee. SPARE was managed by a multidisciplinary 
trial management group and overseen by independent data monitoring (IDMC) and trial 
steering (TSC) committees. 
 
Results 
 
Patient screening and recruitment 
The first participant was recruited on 20/07/2007 and the trial closed to recruitment 
on 12/02/2010 with 45 patients accrued on the advice of the IDMC and TSC due to 
failure to achieve target (stop/go) accrual rates . 
Participating sites were requested to submit anonymised screening logs to the central 
coordinating centre on a regular basis throughout recruitment, to report patients with 
T2/T3 N0 M0 bladder cancer who may be eligible for the trial. 796 patients were 
reported, of whom 490 were ineligible, the majority of whom were not fit enough to 
receive all three SPARE treatment modalities – chemotherapy, cystectomy and 
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radiotherapy. A further 141 potentially eligible patients were not approached regarding 
participation, largely due to the complexity of the patient referral pathway which meant 
that they were not identified as potentially eligible by the participating centre prior to 
radical treatment commencing (22).  
45/165 patients approached to participate consented, with 25 allocated to the radical 
cystectomy group and 20 to selective bladder preservation. Of the 120 patients 
approached who declined, radiotherapy was preferred by 51 and surgery by 25 
(unknown 44) (Figure 2).  
 
Baseline characteristics and compliance with allocated treatment (Table 1) 
23/23 (100%) radical cystectomy patients (2 missing) and 17/20 (85%) selective 
bladder preservation patients responded to neoadjuvant chemotherapy (P=0.092). 35 
of these 40 patients with a response to neoadjuvant chemotherapy received cycle 4 in 
accordance with the protocol. 
 
Deviations from protocol defined treatment were frequent (Figure 2). 36/45 (80.0%, 
95% CI:, 65.4% to 90.4%) received definitive treatment according to allocated group. 
19/25 (76%, 95% CI: 54.9% to 90.6%) patients allocated radical cystectomy underwent 
cystectomy with 6 (24%) receiving radiotherapy.  
 
In the selective bladder preservation group, 17/20 (85.0%, 95% CI: 62.1% to 96.8%) 
received protocol defined treatment; 15/20 selective bladder preservation patients 
(75%, 95% CI: 50.9% to 91.3%) responded to neoadjuvant chemotherapy and received 
radiotherapy per protocol and 2/20 patients (10%, 95% CI: 1.2% to 31.7%) did not 
respond to chemotherapy and proceeded to cystectomy per protocol. The other three 
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patients were not treated in accordance with the selective bladder preservation 
strategy: 1 non-responder had radiotherapy after 3 cycles of neoadjuvant 
chemotherapy rather than proceeding to radical cystectomy; 2 responded yet had 
radical cystectomy (1 after 3 and 1 after all 4 cycles of neoadjuvant chemotherapy).  
 
22 participants overall (16 selective bladder preservation; 6 radical cystectomy) 
received radiotherapy, two with concomitant radiosensitisation. 5 of the 22 (22.7%; 
95% CI: 7.8% to 45.4%) radiotherapy recipients subsequently underwent salvage 
cystectomy, all due to recurrent bladder cancer (3 MIBC, 2 NMIBC). The long term 
bladder preservation rate in the selective bladder preservation group was 12/20 (60%) 
and was 11/15 (73%) in those SBP patients who received RT per protocol. 
 
Toxicity 
More patients undergoing radical cystectomy had CTC grade 3-4 toxicity (16/23 (70%) 
for cystectomy; 8/22 (36%) for radiotherapy: P=0.038) (12/23 (52%) and 6/22 (27%) 
respectively if erectile dysfunction is excluded) (Table 2, Figure 3). The most common 
CTC G1-4 toxicity in patients undergoing cystectomy was fatigue (15/23 (65%)); and in 
patients receiving radiotherapy was fatigue and nocturia (both 12/22 (55%)). 
 
Cancer control and survival 
Median follow up is 58.0 months (IQR 44.3–61.3). The HR for the randomised 
comparison of overall survival was 3.05; 95% CI: 0.92 to 10.15) (Figure 4). Considering 
groups defined by definitive treatment received gave a HR of 1.83 (95% CI: 0.55 to 6.07) 
(Figure S1). Given the wide confidence intervals of the estimate, a survival difference 
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between groups can be neither confirmed nor excluded and non-inferiority cannot be 
claimed.  
 
LRR rate at two years was lower in patients randomised to radical cystectomy at 15.3% 
(95% CI: 5.2% to 40.5%) versus 68.9% (95% CI: 42.5% to 91.5%) in the selective 
bladder preservation group (Figure 4). Seven patients in the selective bladder 
preservation group developed NMIBC recurrence of whom five are long term survivors 
after salvage treatment. There was no evidence of difference in MFS (Figure 4) or DSS 
between randomised groups.  
 
Quality of life 
Baseline subscale scores were similar between groups. After 12 months patients who 
received radiotherapy showed improvement in mean global health status and social 
functioning whilst these declined in the cystectomy group (Table 3). However, the 
confidence limits of the estimates of differences between groups are wide (Figure 5). 
Changes over time in BLM30 single items scores suggest a decline in body image and 
male sexual problems after radical cystectomy that is less evident in radiotherapy 
patients (Figure 6). With both treatments there is an improvement in future 
perspectives with time.  
 
Discussion 
SPARE closed due to failure to meet the predefined minimum target recruitment rate, 
even though there had been extensive efforts and qualitative research to support 
recruitment (16, 17, 22).  
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One key criterion for assessing feasibility of phase III was to demonstrate acceptability 
of the randomised treatment strategies and viability of use of chemotherapy response 
to select patients for radiotherapy. At least 60% of those in the selective bladder 
preservation group were anticipated to receive radiotherapy per protocol. Whilst an 
initial bladder preservation rate of 75% was observed in those receiving radiotherapy 
per protocol in the selective bladder preservation arm, the small number of patients 
recruited resulted in wide CIs spanning 60% such that the threshold to warrant 
continuation to phase III was not met. A 90% cystectomy rate was anticipated in the 
radical cystectomy group but cystectomy was only performed in 76% of patients in this 
group.  
 
Low randomisation rates and frequent deviations from allocated treatment suggest 
patients have a reluctance to allow randomisation to determine which of two 
contrasting treatment strategies they should receive. In accordance with the principles 
of good clinical practice, patients were made aware prior to randomisation that they 
could change their mind about participation in the trial at any stage without affecting 
the level of care they would receive. They were, however asked not to join the trial 
unless they believed they would be willing for their treatment to be determined by the 
SPARE protocol. Despite this request a high proportion of treatment deviations, largely 
driven by patient choice, were observed. 
 
An additional contributor to early closure of the study was the smaller than anticipated 
number of patients eligible for all treatment modalities. This, in addition to a lack of 
equipoise amongst clinicians (17), had a major impact. Undoubtedly a proportion of 
patients approached for this study demonstrated an appetite for bladder preservation; 
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many selecting radiotherapy when declining randomisation and a substantial 
proportion of participants receiving radiotherapy when not mandated by the protocol. 
This suggests that patients’ wishes for bladder preservation should be considered when 
discussing treatment options.  
 
Robust conclusions cannot be made due to the limited sample size and are further 
complicated by poor compliance with assigned treatment strategy and differences in 
neoadjuvant chemotherapy response rates between the two randomised groups. 
Overall response to neoadjuvant chemotherapy was consistent with pilot work (15) and 
was higher than the pathological complete response rates in cystectomy specimens 
reported in trials of neoadjuvant chemotherapy followed by radical cystectomy (11, 23). 
This would suggest that cystoscopic examination understages some patients and 
supports the rationale for recommending additional treatment even for a clinically 
normal looking bladder.  
 
LRR free survival was worse after radiotherapy, mainly due to the incidence of NMIBC 
which was more frequent than invasive recurrence. This is reported in other bladder 
preserving series(15, 24, 25) and suggests the bladder remains at high risk of 
developing second primary disease. This may indicate a role for preventative therapy 
such as that undertaken for NMIBC. Many cases of NMIBC can be salvaged with local 
treatment thus the bladder preservation rate remained high as reported elsewhere (15, 
25). 
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When comparing radical radiotherapy to radical cystectomy, considering the frequency 
of ‘non-salvageable’ recurrences may be more appropriate than overall recurrence 
rates. In this study, the rate of non-salvageable recurrences in responders to 
neoadjuvant chemotherapy is similar for radical cystectomy (4/23) and selective 
bladder preservation (5/17), as are OS and MFS. Observations from this randomised 
trial are consistent with the results of population based studies(7, 26-28), non-
randomised single institution studies (6) and cross study comparisons (4), 
demonstrating little evidence of inferior survival following bladder preservation when 
compared to cystectomy. A recent review of chemo-radiotherapy studies for MIBC 
reported bladder cancer specific and overall survival rates of 50%-82% and 36%-74% 
respectively (29), similar to those seen in like-for-like cystectomy series. If, as our 
results suggest, radiotherapy has less impact on quality of life than radical cystectomy, 
this would provide additional rationale for consideration of bladder sparing therapy. 
 
Few radiotherapy recipients had concomitant chemo-radiotherapy which has since 
been shown to significantly improve clinical outcomes (24). The technical delivery of 
radiotherapy has also improved with the advent of adaptive and image guided 
techniques (30-32), so one may expect improved outcomes with radiotherapy in the 
future. Likewise developments in surgery with increasing use of bladder reconstruction, 
enhanced recovery pathways(33) and minimally invasive techniques (34, 35) should 
result in benefits for patients. 
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The poor outcome of participants whose tumours did not respond to neoadjuvant 
chemotherapy, whether or not they underwent cystectomy, remains a concern and has 
been seen in other studies(15). Alternative systemic or palliative treatment options 
should perhaps be explored in this population. 
 
Identification of predictive markers to help select patients for whom organ preservation 
may be a suitable option remains important. Recent work suggests that bladder cancer 
may consist of a variety of genetic sub-types. It would be of interest to understand if 
certain of these subtypes are more or less likely to respond to chemotherapy or 
radiotherapy (36). Alternative candidates may be markers of DNA repair, with recently 
published work on MRE11 and TIP60 showing promising initial results(37, 38). These 
markers will need to be validated and then tested prospectively. Given experiences in 
SPARE, design of any such study will need to consider the powerful influence of patient 
and clinician preferences and issues of equipoise.   
 
Conclusions 
 
A randomised phase III trial comparing selective bladder preservation and cystectomy 
after neoadjuvant chemotherapy was not feasible. Due to the small number of 
participants, firm conclusions about disease and toxicity outcomes following these 
interventions cannot be drawn, although high rates of bladder preservation appear to 
be achievable in chemotherapy responders without compromising OS. 
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Figure 1 Trial schema 
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Figure 2 Patient flow through trial 
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Table 1 Baseline characteristics and compliance with allocated treatment 
 
  Cystectomy SBP Total 
  (N=25) (N=20) (N=45) 
 
N (%) N (%) N (%) 
Tumour characteristics 
Gender       
Male 22 (88) 18 (90) 40 (89) 
Female 3 (12) 2 (10) 5 (11) 
Age       
Mean (SD) 67.6 (6.1) 63.3 (8.5) 65.7 (7.5) 
Median (min, max) 67 (58.2, 81.1) 63.2 (37.9, 75.2) 65.3 (37.9, 81.1) 
Patient characteristics 
Clinical stage       
T2 22 (88) 14 (70) 36 (80) 
T3a 0 (0) 2 (10) 2 (4) 
T3b 1 (4) 2 (10) 3 (7) 
Missing 2 (8) 2 (10) 4 (9) 
Pathological stage       
pT1 1 (4) 1 (5) 2 (4) 
pT2 24 (96) 19 (95) 43 (96) 
Tumour grade       
G2 1 (4) 3 (15) 4 (9) 
G3 24 (96) 17 (85) 41 (91) 
Type of chemotherapy       
Gem-Cis 24 (96) 20 (100) 44 (98) 
Other (Gem-Carbo) 1 (4) 0 (0) 1 (2) 
Compliance with allocated treatment 
Responder 23 (92) 17 (85) 40 (89) 
Cystectomy 18 (72) 2 (10) 20 (44) 
Radiotherapy 5 (20) 15 (75) 20 (44) 
Non-responder 0 (0) 3 (15) 3 (7) 
Cystectomy - (-) 2 (10) 2 (4) 
Radiotherapy - (-) 1 (5) 1 (2) 
Response data missing 2 (8) 0 (0) 2 (4) 
Cystectomy 1 (4) - (-) 1 (2) 
Radiotherapy 1 (4) - (-) 1 (2) 
Greyed cells indicate correct definitive treatment based on allocation and response to 
chemotherapy. 
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Table 2a Worst overall toxicity grade by treatment received for all participants 
 
  
Cystectomy Radiotherapy Total 
(N=23) (N=22) (N=45) 
CTCAE v3 
grade 
N (%) N (%) N (%) 
0 0 (0) 0 (0) 0 (0) 
1 2 (9) 6 (27) 8 (18) 
2 5 (22) 8 (36) 13 (29) 
3 10 (43) 8 (36) 18 (40) 
4 6 (26) 0 (0) 6 (13) 
Total G0-2 7 (30) 14 (64) 21 (47) 
Total G3-4* 16 (70) 8 (36) 24 (53) 
*2-sided Fisher’s exact test comparing number G3-4 events 
between the two groups P=0.038 
 
 
Table 2b as table 2a, excluding erectile dysfunction 
  
Cystectomy Radiotherapy Total 
(N=23) (N=22) (N=45) 
CTCAE v3 
grade 
N (%) N (%) N (%) 
0 0 (0) 0 (0) 0 (0) 
1 4 (17) 7 (30) 11 (48) 
2 7 (30) 9 (39) 16 (70) 
3 6 (26) 6 (26) 12 (52) 
4 6 (26) 0 (0) 6 (26) 
Total G0-2 11 (48) 16 (70) 27 (117) 
Total G3-4* 12 (52) 6 (26) 18 (78) 
*2-sided Fisher’s exact test comparing number G3-4 events 
between the two groups P=0.130 
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Figure 3a Time to first G3-4 toxicity by definitive treatment received 
Patients in the radiotherapy group are censored at time of salvage cystectomy if this 
occurs prior to grade 3-4 adverse event 
 
 
Figure 3b (excluding erectile dysfunction) 
Patients in the radiotherapy group are censored at time of salvage cystectomy if this 
occurs prior to grade 3-4 adverse event 
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Figure 4 
Time to event endpoints 
Presented by allocated treatment for the population of patients who responded to 
chemotherapy  
 
In all cases, patients with a second primary without a prior event were censored at 
the date of second primary and patients without an event were censored at the date 
last seen. 
 
Comparisons between groups were made using the Log Rank test. 
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LRR  
 
LRR: patients diagnosed with distant recurrence without a prior loco-regional 
recurrence were censored at the date of diagnosis of distant recurrence and patients 
who underwent a cystectomy for reasons other than recurrence were censored at 
the date of cystectomy 
Note: of the 7 patients in the SBP group who underwent radiotherapy per protocol and 
had NMIBC recurrence, 5 are long term survivors while 2 have died following metastatic 
recurrence. 1 SBP patient underwent radiotherapy per protocol, had MIBC and 
metastatic recurrence and died despite undergoing salvage cystectomy. 
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MFS  
 
*events occurred after 60 months 
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Table 3 
Change in EORTC QLQ C30 subscale scores from baseline to month 12 
 
 
Cystectomy Radiotherapy Cystectomy vs Radiotherapy 
 
n 
Mean change 
from BL 
99% CI n 
Mean change 
from BL 
99% CI 
Difference* 
(Radiotherapy-
Cystectomy) 
99% CI 
Global health status 18 -11.6 -31.9 to 8.7 12 7.64 -11.9 to 27.1 14.2 -11.1 to 39.5 
Physical function 18 -10 -23.9 to 3.9 10 -2.67 -22.9 to 17.6 7.76 -13.9 to 29.4 
Role function 18 -8.3 -32.8 to 16.1 12 0 -25.5 to 25.5 15.27 -16.3 to 46.9 
Emotional function 18 6.5 -6.4 to 19.4 12 6.25 -7.3 to 19.8 3.03 -11.9 to 18.0 
Cognitive function 18 6.5 -4.7 to 17.6 12 -2.78 -16.8 to 11.2 -2.59 -14.5 to 9.3 
Social function 18 -7.4 -35.1 to 20.3 12 4.17 -25.8 to 34.1 16.62 -16.6 to 49.9 
Fatigue 16 -4.9 -28.4 to 18.7 12 -11.11 -35.5 to 13.3 -9.28 -33.2 to 14.7 
Nausea / vomiting 18 -7.4 -17.2 to 2.3 12 0 -14.3 to 14.3 5.46 -8.3 to 19.2 
Pain 18 1.9 -13.7 to 17.4 11 0 -14.2 to 14.2 -2.71 -19.4 to 14.0 
Dyspnoea 18 0 -17.5 to 17.5 11 -3.03 -12.6 to 6.6 -3.47 -23.7 to 16.8 
Insomnia 18 -5.6 -34.0 to 22.9 12 -2.78 -26.5 to 20.9 -7.72 -38.0 to 22.5 
Appetite loss 18 0 -13.5 to 13.5 12 -2.78 -26.5 to 20.9 -3.53 -23.5 to 16.4 
Constipation 18 -7.4 -30.3 to 15.4 12 2.78 -29.6 to 35.2 -2.86 -32.5 to 26.8 
Diarrhoea 18 0 -7.8 to 7.8 12 0 -12.7 to 12.7 -0.69 -11.2 to 9.8 
Financial problems 18 -3.7 -14.4 to 7.0 12 0 0 to 0 1.68 -10.8 to 14.1 
 
Note: Confidence intervals were constructed using Student’s t-distribution. No P-values were calculated. 
Note: High scores indicate better function for functional subscales, and high scores indicate worse symptoms / more problems for all 
other scales. 
*ANOVA difference in the change in 12 month subscale score from baseline between patients receiving radiotherapy and patients 
receiving cystectomy as definitive treatment, adjusting for baseline subscale score. 
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Figure 5: Mean change from baseline in EORTC QLQ-C30 subscales 
 
B/L: baseline; P/T: post-treatment 
Note: high scores indicate better function  
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Figure 6: Mean change from baseline in EORTC QLQ-BLM30 subscales 
 
B/L: baseline; P/T: post-treatment 
Note: High scores indicate better function for functional subscales (sexual function), and high scores indicate worse symptoms / more problems 
for all other scales (denoted *). 
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Note: While the EORTC QLQ-BLM30 module is available for use it had not yet been validated at the time of analysis (i.e. the module had been 
carefully developed and tested for acceptability with patients, but had not undergone psychometric testing in a large international group of 
patients). The suggested subscales for this module are still under review and may change after psychometric analysis. The scoring procedure for the 
sexual function subscale was guided by the validated EORTC QLQ-NMIBC24 questionnaire. 
